Science Setbacks: 2014

This year in life science was marked by paltry federal funding increases, revelations of sequence contamination, and onerous regulations.

Written byMolly Sharlach
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, JERICHOThis year’s federal budgets for scientific research were marked by small increases after last year’s sequestration-related cuts. Biomedical research advocates expressed frustration upon the passage of the omnibus spending bill in January. “The proposed package won’t adequately reverse the damage done by last year’s budget sequester and ensure the nation’s biomedical research enterprise makes continued progress in lifesaving research and development,” said Carrie Wolinetz, president of United for Medical Research, in a statement.

Congress recently agreed on a spending bill for 2015, again with meager increases in science funding. The bill includes a 0.5 percent increase to the National Institutes of Health (NIH) budget, a 2.4 percent increase for the National Science Foundation (NSF), and $25 million in special emergency funding for the Food and Drug Administration (FDA) to oversee the testing of Ebola vaccines and treatments. Other bright spots include allocations for the BRAIN Initiative, new pediatric research, and the National Institute on Aging. The bill also contains policy riders that place specific restrictions on the activities of the NIH, the Environmental Protection Agency, the Department of Agriculture, and other science-related agencies, Scientific American reported.

Even for scientists who succeed in securing federal research dollars, keeping up ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies